23,535
Total Claims
$3.2M
Drug Cost
2,093
Beneficiaries
$1,542
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
+1%
Cost per patient vs peers
$1,542 vs $1,524 avg
+22%
Brand preference vs peers
16.6% vs 13.7% avg
Brand vs Generic
83% generic
Brand: 3,909 claims · $2.9M
Generic: 19,626 claims · $341K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 1,779 | $1.5M |
| Rivaroxaban | 514 | $431K |
| Sacubitril/Valsartan | 367 | $337K |
| Evolocumab | 321 | $231K |
| Empagliflozin | 116 | $82K |
| Evolocumab | 120 | $71K |
| Alirocumab | 97 | $70K |
| Dapagliflozin Propanediol | 73 | $53K |
| Metoprolol Succinate | 1,792 | $29K |
| Rosuvastatin Calcium | 1,378 | $27K |
| Ranolazine | 189 | $26K |
| Ezetimibe | 584 | $17K |
| Diltiazem Hcl | 468 | $15K |
| Hydralazine Hcl | 746 | $15K |
| Dabigatran Etexilate Mesylate | 28 | $14K |
Prescribing Profile
75
Unique Drugs
$2.4M
Patient Profile
75
Avg Age
48%
Female
1.58
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data